Literature DB >> 7347444

Mononuclear stromal reactions in mammary carcinoma, with special reference to medullary carcinomas with a lymphoid infiltrate. Analysis of 108 cases.

R Bässler, A M Dittmann, M Dittrich.   

Abstract

Entities:  

Mesh：

Year:  1981        PMID： 7347444     DOI： 10.1007/bf00430872

Source DB:  PubMed          Journal:  Virchows Arch A Pathol Anat Histol        ISSN： 0340-1227


× No keyword cloud information.
  27 in total

1.  Survival in breast cancer cases in relation to the structure of the primary tumor and regional lymph nodes.

Authors:  M M BLACK; S R OPLER; F D SPEER
Journal:  Surg Gynecol Obstet       Date:  1955-05

2.  Sinus histiocytosis of lymph nodes in cancer.

Authors:  M M BLACK; F D SPEER
Journal:  Surg Gynecol Obstet       Date:  1958-02

3.  Lymph node structure in patients with cancer of the breast.

Authors:  M M BLACK; S KERPE; F D SPEER
Journal:  Am J Pathol       Date:  1953 May-Jun       Impact factor: 4.307

4.  LONGEVITY IN CANCER: A STUDY OF 293 CASES.

Authors:  W C Maccarty
Journal:  Ann Surg       Date:  1922-07       Impact factor: 12.969

5.  Further observations on prognostic factors in cancer of the female breast.

Authors:  S J Cutler; M M Black; T Mork; S Harvei; C Freeman
Journal:  Cancer       Date:  1969-10       Impact factor: 6.860

6.  Palpable axillary lymph nodes in cancer of the breast. Structural and biologic considerations.

Authors:  M M Black; A J Asire
Journal:  Cancer       Date:  1969-02       Impact factor: 6.860

7.  Breast carcinoma. A histological and prognostic study of 650 followed-up cases.

Authors:  T Schiodt
Journal:  Dan Med Bull       Date:  1967-09

8.  Nuclear grade and sinus histiocytosis in cancer of the breast.

Authors:  S J Kister; S C Sommers; C D Haagenses; G H Friedell; E Cooley; A Varma
Journal:  Cancer       Date:  1969-03       Impact factor: 6.860

9.  Immunological characterization of mononuclear cells and morphological findings in patients with mammary carcinoma.

Authors:  W Heidenreich; K Jagla; J Schüssler; P Börner; F Dehnhard; J Deinhardt; J Kalden; H H Peter; H Deicher
Journal:  J Cancer Res Clin Oncol       Date:  1979-09       Impact factor: 4.553

10.  The relative significance of prognostic factors in breast carcinoma.

Authors:  M R Alderson; I Hamlin; M D Staunton
Journal:  Br J Cancer       Date:  1971-12       Impact factor: 7.640
View more
  6 in total

1.  Histopathology of tumour associated sarcoid-like stromal reaction in breast cancer. An analysis of 5 cases with immunohistochemical investigations.

Authors:  R Bässler; F Birke
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1988

2.  Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonist attenuate tumor growth via polarization of neutrophils toward an antitumor phenotype.

Authors:  Sanjeeb Shrestha; Jae Myoung Noh; Shin-Yeong Kim; Hwa-Yong Ham; Yeon-Ja Kim; Young-Jin Yun; Min-Ju Kim; Min-Soo Kwon; Dong-Keun Song; Chang-Won Hong
Journal:  Oncoimmunology       Date:  2015-08-12       Impact factor: 8.110

3.  Lymphoreticular infiltrates in invasive ductal breast cancer. A histological and immunohistological study.

Authors:  H P Horny; H A Horst
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1986

4.  Mitotic rate, DNA distribution, and chromatin in situ sensitivity to heparin in breast cancer.

Authors:  H Weiss; H P Brasching; A Bock; F Mauthner; U Peek
Journal:  Breast Cancer Res Treat       Date:  1990-07       Impact factor: 4.872

5.  Study of the relationship between immunohistologically demonstrated lymphocytes infiltrating human breast carcinomas and patients' survival.

Authors:  H O Wintzer; W Bohle; S von Kleist
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

6.  Regulation of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) and TRAIL receptor expression in human neutrophils.

Authors:  Hidenobu Kamohara; Wataru Matsuyama; Osamu Shimozato; Koichiro Abe; Carole Galligan; Shin-Ichi Hashimoto; Kouji Matsushima; Teizo Yoshimura
Journal:  Immunology       Date:  2004-02       Impact factor: 7.397
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.